Insuficiencia cardíaca descompensada aguda hospitalizada

1. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report fromtheAmericanHeartAssociation. Circulation 2020;141(9):e139–596.

2. Huffman MD, Berry JD, Ning H, et al. Lifetime risk for heart failure among White and Black Americans: cardiovascular lifetime risk pooling project. J Am Coll Cardiol 2013;61(14):1510–7.

3. Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep 2013;10(4):401–10.

4. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355(3):251–9.

5. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007; 154(2):260–6.

6. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002;287(5):628–40.

7. Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory

of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2019;74(15): 1966–2011.

8. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011;377(9766):658–66.

9. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62(16):e147–239.

10. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017;70(6):776–803.

11. Stienen S, Salah K, Moons AH, et al. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-guided therapy in acute decompensated heart failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions?). Circulation 2018;137(16):1671–83.

12. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019;380(6):539–48.

13. Felker GM, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2017; 318(8):713–20.

14. Felker GM, Fiuzat M, Thompson V, et al. Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes. Circ Heart Fail 2013;6(6):1172–9.

15. Felker GM, Fiuzat M, Shaw LK, et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012;5(1):72–8.

16. Breidthardt T, Balmelli C, Twerenbold R, et al. Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. J Card Fail 2013;19(12):821–8.

17. Gaggin HK, Szymonifka J, Bhardwaj A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail 2014;2(1):65–72.

18. Uriel N, Sayer G, Imamura T, et al. Relationship between noninvasive assessment of lung fluid volume and invasively measured cardiac hemodynamics. J Am Heart Assoc 2018;7(22):e009175.

19. Pivetta E, Goffi A, Nazerian P, et al. Lung ultrasound integrated with Clinical assessment for the diagnosis of acute decompensated heart failure in the emergency department: a randomized controlled trial. Eur J Heart Fail 2019;21(6): 754–66.

20. Buessler A, Chouihed T, Duarte K, et al. Accuracy of several lung ultrasound methods for the diagnosis of acute heart failure in the ED: a multicenter prospective study. Chest 2020;157(1):99–110.

21. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364(9):797–805.

612 Mitter & Pinney 22. Testani JM, Cappola TP, McCauley BD, et al. Impact of worsening renal function during the treatment of decompensated heart failure on changes in renal function during subsequent hospitalization. Am Heart J 2011;161(5):944–9.

23. Vardeny O, Wu DH, Desai A, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 012; 60(20):2082–9.

24. Cox ZL, Hung R, Lenihan DJ, et al. Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial. JACC Heart Fail 2019;8(3):157–68.

25. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA

2007;297(12):1319–31.

26. Griffin M, Soufer A, Goljo E, et al. Real world use of hypertonic saline in refractory acute decompensated heart failure: a U.S. center’s experience. JACC Heart Fail 2020;8(3):199–208.

27. Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013;310(23):2533–43.

28. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361(25):2436–48.